Who are AK112 with SCRT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SINECATECHINS, PODOFILOX, POLIDEXIDE SULFATE, SUTILAINS, Continue NA treatment, PF-07275315-dose 3.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ak112-with-scrt.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

AK112 with SCRT — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AK112 with SCRT (AK112 with SCRT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Small molecule. Area: Unknown.

phase 2 Small molecule Unknown Unknown Small molecule Live · refreshed every 30 min

Target snapshot

AK112 with SCRT (AK112 with SCRT) — fan li. AK112 with SCRT is a small molecule that targets the molecular target to exert its therapeutic effect.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AK112 with SCRT TARGET	AK112 with SCRT	fan li	phase 2	Small molecule	Unknown
SINECATECHINS	SINECATECHINS		marketed	Polyphenols	Unknown	2006-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
POLIDEXIDE SULFATE	POLIDEXIDE SULFATE		marketed	Unknown	Unknown	1974-01-01
SUTILAINS	SUTILAINS		marketed	Unknown	Unknown	1969-01-01
Continue NA treatment	Continue NA treatment	University Health Network, Toronto	marketed	Unknown	Unknown
PF-07275315-dose 3	pf-07275315-dose-3	Pfizer	marketed	small molecule	unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-10-02 — SINECATECHINS · 7858662 · Formulation · US

Sponsor landscape (Small molecule class)

Pfizer · 3 drugs in this class
Akorn, Inc. · 1 drug in this class
Guangdong Hengrui Pharmaceutical Co., Ltd · 1 drug in this class
Health Research, Inc. · 1 drug in this class
Imperial College London · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Nanjing Sanhome Pharmaceutical, Co., Ltd. · 1 drug in this class
Second Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
UroGen Pharma Ltd. · 1 drug in this class
Abivax S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AK112 with SCRT — Competitive Intelligence Brief. https://druglandscape.com/ci/ak112-with-scrt. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing